No Data
Memo for next week.
On November 11 (Monday), the holiday markets in the USA, France, and Canada are closed. Reserve Bank of New Zealand's fourth-quarter inflation expectations for the next two years: previous value 2.03%. Japan's October banks (including trusts) lending rate: previous value increased by 2.7%. Japan's September trade account: predicted deficit of 66.2 billion yen; previous deficit of 377.9 billion yen. Japan's September current account: predicted surplus of 3.4327 trillion yen; previous surplus of 3.8036 trillion yen. Japan's October economic observers' current situation index: predicted 47.1; previous value 47.8. Japan's October economic observers' future outlook index: predicted 49.2; previous value 49.7.
InnoCare Pharma (SEHK:9969) Achieves Key Milestone With ICP-488 Phase II Success in Psoriasis Treatment
Innocare (09969.HK) plans to hold a board of directors meeting on November 11 to approve the third quarter performance.
Gloryhui October 28th | innocare (09969.HK) announced that the board of directors will hold a meeting on November 11, 2024 (Monday) to consider and approve the unaudited third quarter performance of the company and its subsidiaries for the nine months ending September 30, 2024, as well as its release.
INNOCARE: DATE OF BOARD MEETING
Jefferies Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)
Innocare (688428) Company's first coverage report: Leading the global hematologic field, opening up the second growth curve of self-immunization track.
Deeply cultivating the dual tracks of tumor and self-immunity, the company's core products have entered the harvest period with two core products already approved for listing, and a total of 13 clinical pipeline projects covering various areas such as hematologic malignancies, autoimmune diseases, solid tumors, etc. Hematologic malignancies are the focus of the company's research and development.
No Data
No Data